CDK4 and breast cancer: However, in Turkey, the frequency of ILD development related explicitly to CDK4/6 inhibitors used in breast cancer, the impact of different CDK4/6 inhibitor molecules, and additional risk factors contributing to this frequency have not yet been identified.